Evidence map›Paper›PMID 36418811›Full record

ReviewGlycoconjugate journal2023

Plant lectins as versatile tools to fight coronavirus outbreaks.

Mathias Simplicien, Pierre Pério, Jan Sudor, Annick Barre, Hervé Benoist, Els J M Van Damme, Pierre Rougé

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Glycoconjugate journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mathias SimplicienInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France.
Pierre PérioInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France.
Jan SudorInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France.
Annick BarreInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France.
Hervé BenoistInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France.
Els J M Van DammeDepartment of Biotechnology, Faculty of Bioscience Engineering, Ghent University, Proeftuinstraat 86, B- 9000, Ghent, Belgium.
Pierre RougéInstitut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062, Toulouse, France. pierre.rouge.perso@gmail.com.ORCID http://orcid.org/0000-0002-9936-7843
Université Toulouse III - Paul Sabatier · FRGhent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The S protein forming the homotrimeric spikes of pathogenic beta-coronaviruses, such as MERS-CoV, SARS-CoV and SARS-CoV-2, is a highly glycosylated protein containing mainly N-glycans of the complex and high-mannose type, as well as O-glycans. Similarly, the host cell receptors DPP4 for MERS-CoV and ACE2 for SARS-CoV and SARS-CoV-2, also represent N- and O-glycosylated proteins. All these glycoproteins share common glycosylation patterns, suggesting that plant lectins with different carbohydrate-binding specificities could be used as carbohydrate-binding agents for the spikes and their receptors, to combat COVID19 pandemics. The binding of plant lectins to the spikes and their receptors could mask the non-glycosylated receptor binding domain of the virus and the corresponding region of the receptor, thus preventing a proper interaction of the spike proteins with their receptors. In this review, we analyze (1) the ability of plant lectins to interact with the N- and O-glycans present on the spike proteins and their receptors, (2) the in vitro and in vivo anti-COVID19 activity already reported for plant lectins and, (3) the possible ways for delivery of lectins to block the spikes and/or their receptors.

Indexed as

COVID-19Severe acute respiratory syndrome-related coronavirusHumansPlant LectinsPolysaccharidesSARS-CoV-2Spike Glycoprotein, CoronavirusPlant LectinsPolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Aleuria aurantia lectin (AAL)Beta-coronavirusesCon ACOVID-19Galanthus nivalis agglutinin (GNA)Lens culinaris lectin (LcA)Man-specific lectinMERS-CoVMorus nigra lectin (Morniga-G)Pisum sativum lectin (PsA)Sambucus nigra lectin (SNA-I).SARS-CoVSARS-CoV-2

Identifiers

PMID36418811
PMCPMC9684959
OpenAlexW4309883521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.